Loading clinical trials...

Molecular Biomarkers for Sepsis | Clinical Trials | Clareo Health

TERMINATED

Molecular Biomarkers for Sepsis

Prospective Study to Discover New Biomarkers for Early Detection of Sepsis and Prediction of Sepsis-related Mortality in Patients With Severe Community Acquired Pneumonia (sCAP)

NCT04280354•University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

Summary

This multi-center observational case-control study in Intensive Care Unit (ICU) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP) -associated sepsis at an earlier stage and predict sepsis-related mortality. Patients with sCAP (cases) will be profoundly characterized over time regarding the development of sepsis and compared with control patients. The mechanisms and influencing factors on the clinical course will be explored with most modern -omics technologies allowing a detailed characterisation. These data will be analysed using machine learning algorithms and multi-dimensional mathematical models.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Admission to the ICU of one of the participating centers.
•Cases: severe community acquired pneumonia with requirement for ICU admission.
•Controls: Clinical phenotype of inflammation not due to suspected sepsis In addition, control patients will be patients with fever \>38°C, CRP \>100mg/L, no infection focus expected in ≥ 24h.
•All required sample types can most likely be collected within the first 24h visits.
•Expected ICU stay of more than 24h.

Exclusion Criteria

•Admission to the hospital within the prior 14 days.
•Patients with psychosis
•Evidence of a hospital acquired pneumonia.
•One of the following respiratory conditions: Acute exacerbation of chronic obstructive pulmonary disease (COPD) or bronchiectasis, acute severe asthma, aspiration pneumonia, tuberculosis, clinical suspected viral pneumonia without bacterial infection, cardiogenic pulmonary oedema.
•Patients with an acute respiratory distress Syndrome (ARDS).
•Patient which can be managed as outpatients and do not require an ICU.
•Patient where a transmission to another institution is likely within the next 24h.
•Documented rejection of the general consent or participation to research in general.
•Patients with a palliative situation and a life expectancy due to other diseases (e.g. progressed cancer) less than 28 days.

Locations (15)

Clinical Bacteriology and Mycology, University Hospital Basel

Basel, Switzerland

Infectious Diseases and Hospital Epidemiology, University Hospital Basel

Basel, Switzerland

Intensive Care Unit; University Hospital Basel

Basel, Switzerland

Institute for Infectious Diseases, University of Bern

Bern, Switzerland

Infectious Diseases and Hospital Epidemiology, University Hospital Bern

Bern, Switzerland

Intensive Care Unit, University Hospital Bern

Bern, Switzerland

Clinical Bacteriology, University Hospital Geneva

Geneva, Switzerland

Infectious Diseases and Hospital Epidemiology, University Hospital Geneva

Geneva, Switzerland

Intensive Care Unit, University Hospital Geneva

Geneva, Switzerland

Clinical Microbiology, University Hospital Lausanne

Lausanne, Switzerland

Key Dates

Start Date

February 16, 2022

Primary Completion Date

July 31, 2022

Completion Date

July 31, 2022

Last Updated

May 9, 2024

Enrollment

ACTUAL participants

Conditions

SepsisSevere Community-acquired Pneumonia (sCAP)Infection, Bacterial

Interventions

compare data patterns by data-driven algorithms to determine sepsis

OTHER

compare data patterns by data-driven algorithms to predict sepsis-related mortality

OTHER

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm

NCT04850456

Critical IllnessSepsis, Severe

View study

RECRUITING

A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children

NCT04955210

Critical IllnessSevere Sepsis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Molecular Biomarkers for Sepsis

Inclusion Criteria

Exclusion Criteria

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm

A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit

African Survey on Sepsis Knowledge (ASK)